Can I read Molecular Classification System Identifies Invasive Breast Carcinoma Patients Who Are Most Likely and Those Who Are Least Likely to Achieve a Complete Pathologic Response After Neoadjuvant Chemotherapy on EtoBox?

Molecular Classification System Identifies Invasive Breast Carcinoma Patients Who Are Most Likely and Those Who Are Least Likely to Achieve a Complete Pathologic Response After Neoadjuvant Chemotherapy by Neal S. Goldstein; David Decker; Dawn Severson; Scott Schell; Frank Vicini; Jeffrey Margolis; Nayana S. Dekhne is a Medicine article available to read on EtoBox.

What is Molecular Classification System Identifies Invasive Breast Carcinoma Patients Who Are Most Likely and Those Who Are Least Likely to Achieve a Complete Pathologic Response After Neoadjuvant Chemotherapy about?

## Abstract ## BACKGROUND. The molecular classification system categorizes invasive breast carcinomas according to their key driving biomarkers. In the current study, the authors evaluated whether response to neoadjuvant chemotherapy was correlated with the molecular classification groups. ## METHODS. Using immunohistochemistry, the molecular classification group (luminal‐A, luminal‐B, HER‐2–variant, HER‐2–classic, and basal phenotype) was retrospectively determined in 68 breast cancer patients who received neoadjuvant treatment. ## RESULTS. A total of 28 carcinoma patients (41.2%) achieved a compete pathologic response (CPR), including 2 of 15 patients classified as having luminal‐A (13.3%), 4 of 16 patients classified as having luminal‐B (25.0%), 10 of 12 patients classified as having HER‐2–classic (83.3%), none of the 4 patients classified as having HER‐2–variant, and 12 of 21 patients classified as having basal phenotype (57.1%) neoplasms. The CPR rate among patients with the HER‐2–classic and basal neoplasms was 67% (22 of 33 neoplasms), compared with 17.1% (6 of 35 neoplasms) in the non‐HER‐2–classic/basal combined group (__P__ < .001). Eleven carcinomas were initially diagno

Who reads Molecular Classification System Identifies Invasive Breast Carcinoma Patients Who Are Most Likely and Those Who Are Least Likely to Achieve a Complete Pathologic Response After Neoadjuvant Chemotherapy?

Author

Neal S. Goldstein; David Decker; Dawn Severson; Scott Schell; Frank Vicini; Jeffrey Margolis; Nayana S. Dekhne

Publisher

John Wiley and Sons; Wiley (John Wiley & Sons); John Wiley & Sons Inc.; Wiley (ISSN 0008-543X)

Published

2007

Language

EN

Field

Medicine (Health Sciences)